ArticleJournal of the Canadian Association of Gastroenterology2019
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.
Article in Journal of the Canadian Association of Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04733456 (Evaluation of Brain Activity and Oxygenation Using Near-infrared Spectroscopy), which is not on this map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Brain Activity and Oxygenation Using Near-infrared Spectroscopy (NIRS) in Inflammatory Bowel Disease (IBD) Patients
Who cites it
81 citing papers in PubMed, 157 citations in OpenAlex.
- Anti-inflammatory and antioxidative stress effects ofAnnals of medicine and surgery (2012) · 2026Article
- Gestational weight gain and birth outcomes in a large Canadian cohort of pregnant persons with inflammatory bowel disease.Crohn's & colitis 360 · 2026Article
- Balancing safety and effectiveness: parent preferences for fecal microbiota transplant and established therapies in pediatric inflammatory bowel disease-results of a multicenter Canadian study.Crohn's & colitis 360 · 2026Article
- Identification of Symptom Clusters and Core Symptoms in Inflammatory Bowel Disease: A Network Analysis in Chinese Cohorts.Gastroenterology research and practice · 2026Article
- Article
- A systematic review of inflammatory bowel disease in Kazakhstan: prevalence, risk factors, and genetic insights.Future science OA · 2025Review
- Pioglitazone mitigates acetic acid-induced colitis in rats via epigenetic-modulation and antioxidant mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Global Trends in the Research of Ulcerative Colitis Treatments (2021-2025): A Bibliometric Review.Cureus · 2025Review
- Incidence of Inflammatory Bowel Disease in Children.Gastroenterology research · 2025Article
- Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients' perspectives.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Pregnancy-onset inflammatory bowel disease: A case report.Obstetric medicine · 2025Article
- Characterization of the salivary microbiome of adults with inflammatory bowel disease.Journal of oral microbiology · 2025Article
- Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial.Therapeutic advances in gastroenterology · 2025Article
- Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.PharmacoEconomics - open · 2025Article
- Prevalence of stricturing, penetrating complications and extraintestinal manifestations in inflammatory bowel disease detected on cross-sectional imaging in a tertiary care setting.United European gastroenterology journal · 2024Article
- Changing epidemiology of inflammatory bowel disease in children and adolescents.International journal of colorectal disease · 2024Article
- Perceptions and Prevalence of Cannabis Use in Women With Inflammatory Bowel Disease of Reproductive Age: A Cross-Sectional Study.Journal of the Canadian Association of Gastroenterology · 2024Article
- Gut Microbiome-Related Anti-Inflammatory Effects of Aryl Hydrocarbon Receptor Activation on Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- The Fundamentals of Inflammatory Bowel Disease Management in Pregnancy: A Practical Review for the Gastroenterologist.Journal of the Canadian Association of Gastroenterology · 2024Review
- Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.Therapeutic advances in chronic disease · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canada has among the highest incidence and prevalence of inflammatory bowel disease (IBD) in the world. After decades of rising incidence of IBD in Canada during the 20th Century, the prevalence of IBD in 2018 is 0.7% of the Canadian population. Forecasting models predict that prevalence of IBD will continue to rise to 1.0% of the population by 2030. In 2018, the number of Canadians living with IBD is approximately 270,000 and is predicted to rise to 403,000 Canadians in 2030. Inflammatory bowel disease affects all age groups with adolescents and young adults at highest risk of diagnosis. Canadians of all ethnicities are being diagnosed with IBD including known high-risk groups such as Ashkenazi Jews and offspring of South Asian immigrants who were previously thought to be low risk. Moreover, IBD has evolved into a global disease with rising incidence in newly industrialized countries in Asia and South America. The causes of IBD remain unsolved; however, the high rates of disease in Western countries and its emergence in newly industrialized countries suggest that environmental factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease. HIGHLIGHTS: 1. Canada continues to have among the highest prevalence of IBD in the world.2. Today, approximately 270,000 Canadians live with IBD. By 2030 it is estimated that nearly 403,000 Canadians will have a diagnosis of IBD.3. Inflammatory bowel disease has become a worldwide disease with increasing rates in Asia, Africa, and South America-continents where IBD was rarely diagnosed prior to 1990.4. The causes of IBD are unknown, but the high rates of disease over the past 60 years in Western countries and the emergence of disease in developing countries suggest that factors associated with urbanization, modernization, or Western diets may be pertinent to understanding the pathogenesis of the disease.5. Many of the leading hypotheses as to the causes of IBD tie in with alteration of the gut microbiome, the suite of organisms that reside in the bowel and maintain bowel health throughout life. KEY SUMMARY POINTS: 1. The incidence (the number of new diagnoses annually) of IBD rose throughout the 20th century in Canada and then stabilized at the turn of the 21st century.2. The prevalence (the total number of diagnosed persons in the population) of IBD in Canada is among the highest in the world.3. Today, 270,000 (0.7%, or 7 in 1000) Canadians are estimated to live with IBD. By 2030, that number is expected to rise to 403,000 Canadians (1% or 1 in 100).4. Inflammatory bowel disease can be diagnosed at any age. However, the age groups that are most likely to be diagnosed are adolescents and young adults from 20 to 30 years of age.5. Inflammatory bowel disease in Canada affects the lives of Canadians of all ethnicities, including known high-risk groups such as Ashkenazi Jews, and those thought previously to be at low risk, such as first-generation offspring of South Asian immigrants.6. Canadian health policy makers will need to prepare the Canadian health care system for the rising burden of IBD.7. As newly industrialized countries in Asia, Africa, and South America are transitioning to a Westernized society, IBD has emerged and its incidence in these countries is rising rapidly.8. The gut microbiome includes microorganisms that maintain digestive health. Thus, changes in the microbiome, which may change the immune system's response to triggers, may be important in initiating and perpetuating IBD.9. A number of factors can alter the gut microbiome and early childhood may be a particularly important time such that breastfeeding, early life diet, use of antibiotics, infections, and other environmental exposures may impact the gut microbiome in such a way that facilitates developing IBD.10. Smoking is associated with an increased risk and worsening disease course of Crohn's disease. Quitting smoking is associated with an increased risk of developing ulcerative colitis. Therefore, never initiating smoking can mitigate the risk for IBD. Educational programs aimed at those at-risk for IBD should emphasize the risk of starting to smoke tobacco.11. Modifying exposure to environmental risk factors associated with the Westernization of society (e.g., Western diet and lifestyles) may provide an avenue for reducing the risk of IBD in Canada and worldwide. GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS: 1. While the incidence of IBD appears to be stabilizing in some regions in Canada, IBD may be occurring more frequently in certain populations such as in children, South Asians, Ashkenazi Jews, and immigrants. Future research should focus on the changing demographics of IBD in Canada.2. The prevalence of IBD will rise steadily over the next decade. To enable better health care system planning and to respond adequately to the increasing burden of IBD, ongoing surveillance of the epidemiology and health services utilization of IBD in Canada is necessary.3. Most studies have focused on the mortality associated with IBD. Future research is necessary to assess health-adjusted life expectancy and overall life expectancy for those living with IBD.4. Analyses of resources, infrastructure, and personnel need to be modeled into the future in order to prepare our health care system for the rising burden of IBD.5. Research on the interaction between genes, microbes, and our environment will inform our understanding of the pathogenesis of IBD, information necessary to prevent IBD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.